Publications & Presentations

Nov 13, 2023

Interim Results from the heart-1 Trial of VERVE-101 & Verve Corporate Updates

AHA

VERVE-101, VERVE-102, VERVE-201

2023

ANGPTL3, PCSK9

Nov 12, 2023

Interim Results from the heart-1 Trial of VERVE-101

AHA

VERVE-101

2023

PCSK9

Aug 28, 2023

An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models

ESC

VERVE-201

2023

ANGPTL3

May 26, 2023

Developing ‘once-and-done’ gene editing medicines to treat cardiovascular disease

EAS

VERVE-101, VERVE-201, GalNAc-LNP

2023

ANGPTL3, PCSK9

May 08, 2023

TIDES 2023 Keynote Address

TIDES

VERVE-101, VERVE-201

2023

ANGPTL3, PCSK9

May 07, 2023

Innovative LNPs for Gene Editing Applications

TIDES

GalNAc-LNP

2023

ANGPTL3, PCSK9

Mar 05, 2023

Preclinical Data Supporting Potential Efficacy of VERVE-201, an Investigational Base Editing Medicine Targeting ANGPTL3

ACC

VERVE-201, GalNAc-LNP

2023

ANGPTL3

Nov 06, 2022

VERVE-101 – an investigational single- course gene editing medicine targeting PCSK9 – durably and potently lowers PCSK9 and LDL-C concentrations in non-human primates

AHA

VERVE-101

2022

PCSK9

Aug 29, 2022

An in vivo CRISPR base editing therapy to inactivate ANGPTL3: nomination of a development candidate for VERVE-201 [presentation]

ESC

VERVE-201, GalNAc-LNP

2022

ANGPTL3